VEGFA and non-small cell lung carcinoma: Bevacizumab is a recombinant anti-VEGF monoclonal antibody FDA-approved for treatment of unresectable, locally-advanced, recurrent, or metastatic NSCLC in combination with paclitaxel and carboplatin [9, 24].